EGFR and adenocarcinoma: For example, for NSCLC adenocarcinoma with gain of function mutations in Epidermal Growth Factor Receptor (EGFR) as well as with EGFR gene amplification, tyrosine kinase inhibitors (EGFR-TKIs) have been developed [1].